A demonstration of GREM1-mediated activation of FGFR1 in vivo (independent from its inhibitory effect on BMP signaling) in prostate cancer would strengthen the argument that GREM1 promotes prostate cancer progression by activating FGFR1. Here, FGFR1 is linked to prostate carcinoma.